Product Name
MYD88, siRNA
Full Product Name
MYD88 siRNA (Human)
Product Synonym Names
Myeloid differentiation primary response protein MyD88
Product Gene Name
MYD88 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q99836
Specificity
MYD88 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human MYD88 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of MYD88 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
MYD88 sirna
siRNA to inhibit MYD88 expression using RNA interference
Applications Tested/Suitable for MYD88 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for MYD88. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001166037.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001172566.1
[Other Products]
UniProt Primary Accession #
Q99836
[Other Products]
UniProt Secondary Accession #
P78397; Q53XS7; B4DKH8; B4DKU4; B4DQ60; B4DQ72; J3KPU4; J3KQ87; J3KQJ6[Other Products]
UniProt Related Accession #
Q99836[Other Products]
Molecular Weight
34,097 Da
NCBI Official Full Name
myeloid differentiation primary response protein MyD88 isoform 5
NCBI Official Synonym Full Names
myeloid differentiation primary response 88
NCBI Official Symbol
MYD88 [Similar Products]
NCBI Official Synonym Symbols
MYD88D
[Similar Products]
NCBI Protein Information
myeloid differentiation primary response protein MyD88
UniProt Protein Name
Myeloid differentiation primary response protein MyD88
Protein Family
Myeloid differentiation primary response protein
UniProt Gene Name
MYD88 [Similar Products]
UniProt Entry Name
MYD88_HUMAN
NCBI Summary for MYD88
This gene encodes a cytosolic adapter protein that plays a central role in the innate and adaptive immune response. This protein functions as an essential signal transducer in the interleukin-1 and Toll-like receptor signaling pathways. These pathways regulate that activation of numerous proinflammatory genes. The encoded protein consists of an N-terminal death domain and a C-terminal Toll-interleukin1 receptor domain. Patients with defects in this gene have an increased susceptibility to pyogenic bacterial infections. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Feb 2010]
UniProt Comments for MYD88
MYD88: Adapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response. Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription. Involved in IL-18-mediated signaling pathway. Activates IRF1 resulting in its rapid migration into the nucleus to mediate an efficient induction of IFN-beta, NOS2/INOS, and IL12A genes. Homodimer. Also forms heterodimers with TIRAP. Binds to TLR2, TLR4, IRAK1, IRAK2 and IRAK4 via their respective TIR domains. Interacts with IL18R1. Interacts with BMX, IL1RL1 and IRF7. Interacts with LRRFIP1 and LRRFIP2; this interaction positively regulates Toll-like receptor (TLR) signaling in response to agonist. Interacts with FLII. LRRFIP1 and LRRFIP2 compete with FLII for MYD88-binding. Interacts with IRF1. Ubiquitous. 4 isoforms of the human protein are produced by alternative splicing.
Protein type: Adaptor/scaffold
Chromosomal Location of Human Ortholog: 3p22
Cellular Component: plasma membrane; endosome membrane; cytosol
Molecular Function: identical protein binding; protein binding; death receptor binding
Biological Process: positive regulation of interleukin-17 production; positive regulation of I-kappaB kinase/NF-kappaB cascade; nerve growth factor receptor signaling pathway; positive regulation of interleukin-23 production; positive regulation of interleukin-6 production; signal transduction; toll-like receptor 10 signaling pathway; toll-like receptor 2 signaling pathway; MyD88-dependent toll-like receptor signaling pathway; toll-like receptor 5 signaling pathway; defense response to Gram-positive bacterium; cell surface receptor linked signal transduction; regulation of inflammatory response; toll-like receptor signaling pathway; positive regulation of interferon type I production; innate immune response; toll-like receptor 9 signaling pathway; inflammatory response; toll-like receptor 4 signaling pathway; negative regulation of apoptosis
Disease: Macroglobulinemia, Waldenstrom, Susceptibility To, 1; Myd88 Deficiency
Research Articles on MYD88
1. Findings support the association between MYD88 mutations and a response to ibrutinib therapy in patients with Waldenstrom's Macroglobulinemia.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
